IC50 values after treament with AX
| Cell line . | Origin . | Growth inhibition (IC50), μM . |
|---|---|---|
| K562 and K562 IMr | CML (BCR-ABL1+) | 5.72 ± 0.31 and 6.24 ± 0.52 |
| KCL22 and KCL22 IMr | CML (BCR-ABL1+) | 2.74 ± 0.52 and 2.86 ± 0.63 |
| BA/F3 | Murine pro B cell line | 3.12 ± 0.09 |
| BA/F3 (T315I) | Murine pro–B-cell line (BCR-ABL1+) | 3.02 ± 0.22 |
| BA/F3 (T315I) PNr | Murine pro–B-cell line (BCR-ABL1+) | 4.02 ± 0.22 |
| BA/F3 (M351T) | Murine pro–B-cell line (BCR-ABL1+) | 3.11 ± 0.12 |
| BA/F3 (E255K) | Murine pro–B-cell line (BCR-ABL1+) | 3.02 ± 0.41 |
| SUP-B15 and SUP-B15 IMr | BCP-ALL (BCR-ABL1+) | 2.9 ± 0.67 and 3.97 ± 0.47 |
| HL60 | AML | 7.17 ± 1.7 |
| Mutz-2 | AML | 10.10 ± 0.46 |
| Kasumi | AML | 6.0 ± 0.03 |
| SEM | BCP-ALL | 5.9 ± 0.07 |
| 697 | BCP-ALL | 3.9 ± 0.10 |
| Cell line . | Origin . | Growth inhibition (IC50), μM . |
|---|---|---|
| K562 and K562 IMr | CML (BCR-ABL1+) | 5.72 ± 0.31 and 6.24 ± 0.52 |
| KCL22 and KCL22 IMr | CML (BCR-ABL1+) | 2.74 ± 0.52 and 2.86 ± 0.63 |
| BA/F3 | Murine pro B cell line | 3.12 ± 0.09 |
| BA/F3 (T315I) | Murine pro–B-cell line (BCR-ABL1+) | 3.02 ± 0.22 |
| BA/F3 (T315I) PNr | Murine pro–B-cell line (BCR-ABL1+) | 4.02 ± 0.22 |
| BA/F3 (M351T) | Murine pro–B-cell line (BCR-ABL1+) | 3.11 ± 0.12 |
| BA/F3 (E255K) | Murine pro–B-cell line (BCR-ABL1+) | 3.02 ± 0.41 |
| SUP-B15 and SUP-B15 IMr | BCP-ALL (BCR-ABL1+) | 2.9 ± 0.67 and 3.97 ± 0.47 |
| HL60 | AML | 7.17 ± 1.7 |
| Mutz-2 | AML | 10.10 ± 0.46 |
| Kasumi | AML | 6.0 ± 0.03 |
| SEM | BCP-ALL | 5.9 ± 0.07 |
| 697 | BCP-ALL | 3.9 ± 0.10 |
IM-sensitive/resistant human- and murine-derived pro–B-cell lines expressing clinically relevant BCR-ABL1 mutant isoforms (T315I, T315I (PNr), M351T, and E255K) were treated with AX at different concentrations for 72 hours, and the average IC50 was then determined by CellTiter-Glo assay (n = 3).
IMr, IM resistant; PNr, ponatinib resistant.